ReviewOncogene2004
Translational regulation by the p210 BCR/ABL oncoprotein.
Review in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Role of the RNA-binding protein La in cancer pathobiology.RNA biology · 2021Review
- αCP Poly(C) binding proteins act as global regulators of alternative polyadenylation.Molecular and cellular biology · 2013Article
- Article
- The role of translation initiation regulation in haematopoiesis.Comparative and functional genomics · 2012Article
- Extensive gene-specific translational reprogramming in a model of B cell differentiation and Abl-dependent transformation.PloS one · 2012Article
- The role of heterogeneous nuclear ribonucleoprotein K in the progression of chronic myeloid leukemia.Medical oncology (Northwood, London, England) · 2010Article
- BCR-ABL promotes neutrophil differentiation in the chronic phase of chronic myeloid leukemia by downregulating c-Jun expression.Leukemia · 2009Article
- Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies.Oncogene · 2007Review
- Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications.The Journal of clinical investigation · 2007Review
- Review
- Autoimmunity as a result of escape from RNA surveillance.Journal of immunology (Baltimore, Md. : 1950) · 2006Article
- Article
- Article
- Aberrant mRNA translation in cancer pathogenesis: an old concept revisited comes finally of age.Oncogene · 2004Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The ability of oncogenic proteins to regulate the rate of translation of specific mRNA subsets may be a rapid and efficient mechanism to modulate the levels and, in many cases, the activity of the corresponding proteins. In the past few years, we have identified several RNA binding proteins with translation regulatory activity whose expression is markedly activated in the blast crisis of chronic myelogenous leukemia, which represents the most malignant disease stage. Perturbation of the activity of some RNA binding proteins suppresses the leukemogenic potential of BCR/ABL-expressing cells. Most importantly, we have identified some of the targets of these RNA binding proteins. Two of these targets, c/ebp alpha and mdm2 mRNAs, are directly relevant for the altered differentiation and survival of leukemic cells. The identification of mRNA targets translationally regulated by RNA binding proteins overexpressed in tumor cells may lead to the development of therapeutic strategies aimed at modulating the translation rate of specific mRNAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.